Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer

Taejeong Oh, Nayoung Kim, Youngho Moon, Myung Soon Kim, Benjamin D. Hoehn, Chan Hee Park, Tae Soo Kim, Namkyu Kim, Hyuncheol Chung, Sungwhan An

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Aberrant DNA methylation has shown promise as a biomarker for the early detection of cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer (CRC), DNA microarray analysis coupled with enriched methylated DNA was performed in primary tumors and compared with adjacent nontumor tissues of 12 patients with CRC at stages I to IV. Stepwise filtering for candidate selection in microarray data analysis yielded a set of genes that are highly methylated across all CRC tumors and that can be used as a composite biomarker for CRC detection. Verification assay identified the SDC2 gene as a potential methylation biomarker for early CRC detection. In clinical validation in tissues from 139 CRC patients, a much higher level of aberrant SDC2 methylation was measured in most primary tumors (97.8%), compared with corresponding nontumor tissue of CRC patients, irrespective of clinical stage. Clinical validation of SDC2 methylation in serum DNA from CRC patients (n = 131) at stages I to IV and from healthy individuals (n = 125) by quantitative methylation-specific PCR demonstrated a high sensitivity of 87.0% (95% CI, 80.0% to 92.3%) in detecting cancers, with a specificity of 95.2% (95% CI, 89.8% to 98.2%). Importantly, sensitivity at stage I was 92.3%, indicating the potential of SDC2 methylation as a blood-based DNA test for early detection of CRC.

Original languageEnglish
Pages (from-to)498-507
Number of pages10
JournalJournal of Molecular Diagnostics
Volume15
Issue number4
DOIs
Publication statusPublished - 2013 Jul 1

Fingerprint

Methylation
Colorectal Neoplasms
Biomarkers
Genome
Early Detection of Cancer
Microarray Analysis
DNA
Genes
Neoplasms
DNA Methylation
Oligonucleotide Array Sequence Analysis
Polymerase Chain Reaction
Serum

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Medicine

Cite this

Oh, Taejeong ; Kim, Nayoung ; Moon, Youngho ; Kim, Myung Soon ; Hoehn, Benjamin D. ; Park, Chan Hee ; Kim, Tae Soo ; Kim, Namkyu ; Chung, Hyuncheol ; An, Sungwhan. / Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. In: Journal of Molecular Diagnostics. 2013 ; Vol. 15, No. 4. pp. 498-507.
@article{4648d2db6d434ca5925bb39737c32aae,
title = "Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer",
abstract = "Aberrant DNA methylation has shown promise as a biomarker for the early detection of cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer (CRC), DNA microarray analysis coupled with enriched methylated DNA was performed in primary tumors and compared with adjacent nontumor tissues of 12 patients with CRC at stages I to IV. Stepwise filtering for candidate selection in microarray data analysis yielded a set of genes that are highly methylated across all CRC tumors and that can be used as a composite biomarker for CRC detection. Verification assay identified the SDC2 gene as a potential methylation biomarker for early CRC detection. In clinical validation in tissues from 139 CRC patients, a much higher level of aberrant SDC2 methylation was measured in most primary tumors (97.8{\%}), compared with corresponding nontumor tissue of CRC patients, irrespective of clinical stage. Clinical validation of SDC2 methylation in serum DNA from CRC patients (n = 131) at stages I to IV and from healthy individuals (n = 125) by quantitative methylation-specific PCR demonstrated a high sensitivity of 87.0{\%} (95{\%} CI, 80.0{\%} to 92.3{\%}) in detecting cancers, with a specificity of 95.2{\%} (95{\%} CI, 89.8{\%} to 98.2{\%}). Importantly, sensitivity at stage I was 92.3{\%}, indicating the potential of SDC2 methylation as a blood-based DNA test for early detection of CRC.",
author = "Taejeong Oh and Nayoung Kim and Youngho Moon and Kim, {Myung Soon} and Hoehn, {Benjamin D.} and Park, {Chan Hee} and Kim, {Tae Soo} and Namkyu Kim and Hyuncheol Chung and Sungwhan An",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.jmoldx.2013.03.004",
language = "English",
volume = "15",
pages = "498--507",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "4",

}

Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. / Oh, Taejeong; Kim, Nayoung; Moon, Youngho; Kim, Myung Soon; Hoehn, Benjamin D.; Park, Chan Hee; Kim, Tae Soo; Kim, Namkyu; Chung, Hyuncheol; An, Sungwhan.

In: Journal of Molecular Diagnostics, Vol. 15, No. 4, 01.07.2013, p. 498-507.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer

AU - Oh, Taejeong

AU - Kim, Nayoung

AU - Moon, Youngho

AU - Kim, Myung Soon

AU - Hoehn, Benjamin D.

AU - Park, Chan Hee

AU - Kim, Tae Soo

AU - Kim, Namkyu

AU - Chung, Hyuncheol

AU - An, Sungwhan

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Aberrant DNA methylation has shown promise as a biomarker for the early detection of cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer (CRC), DNA microarray analysis coupled with enriched methylated DNA was performed in primary tumors and compared with adjacent nontumor tissues of 12 patients with CRC at stages I to IV. Stepwise filtering for candidate selection in microarray data analysis yielded a set of genes that are highly methylated across all CRC tumors and that can be used as a composite biomarker for CRC detection. Verification assay identified the SDC2 gene as a potential methylation biomarker for early CRC detection. In clinical validation in tissues from 139 CRC patients, a much higher level of aberrant SDC2 methylation was measured in most primary tumors (97.8%), compared with corresponding nontumor tissue of CRC patients, irrespective of clinical stage. Clinical validation of SDC2 methylation in serum DNA from CRC patients (n = 131) at stages I to IV and from healthy individuals (n = 125) by quantitative methylation-specific PCR demonstrated a high sensitivity of 87.0% (95% CI, 80.0% to 92.3%) in detecting cancers, with a specificity of 95.2% (95% CI, 89.8% to 98.2%). Importantly, sensitivity at stage I was 92.3%, indicating the potential of SDC2 methylation as a blood-based DNA test for early detection of CRC.

AB - Aberrant DNA methylation has shown promise as a biomarker for the early detection of cancer. To discover novel genes frequently methylated at an early stage in colorectal cancer (CRC), DNA microarray analysis coupled with enriched methylated DNA was performed in primary tumors and compared with adjacent nontumor tissues of 12 patients with CRC at stages I to IV. Stepwise filtering for candidate selection in microarray data analysis yielded a set of genes that are highly methylated across all CRC tumors and that can be used as a composite biomarker for CRC detection. Verification assay identified the SDC2 gene as a potential methylation biomarker for early CRC detection. In clinical validation in tissues from 139 CRC patients, a much higher level of aberrant SDC2 methylation was measured in most primary tumors (97.8%), compared with corresponding nontumor tissue of CRC patients, irrespective of clinical stage. Clinical validation of SDC2 methylation in serum DNA from CRC patients (n = 131) at stages I to IV and from healthy individuals (n = 125) by quantitative methylation-specific PCR demonstrated a high sensitivity of 87.0% (95% CI, 80.0% to 92.3%) in detecting cancers, with a specificity of 95.2% (95% CI, 89.8% to 98.2%). Importantly, sensitivity at stage I was 92.3%, indicating the potential of SDC2 methylation as a blood-based DNA test for early detection of CRC.

UR - http://www.scopus.com/inward/record.url?scp=84879289642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879289642&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2013.03.004

DO - 10.1016/j.jmoldx.2013.03.004

M3 - Article

VL - 15

SP - 498

EP - 507

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 4

ER -